Melanotan II: Broad Reach, Real Cautions

The short version

Melanotan II (MT-II) is a cyclic heptapeptide with the sequence Ac-Nle4-cyclo[Asp5-His6-D-Phe7-Arg8-Trp9-Lys10]-NH2, designed at the University of Arizona in the late 1980s. It activates all five melanocortin receptor subtypes (MC1R through MC5R), making it a non-selective agonist. MC1R stimulation on melanocytes drives skin and hair darkening; central MC4R activation produces the sexual and appetite effects ^[16].

Melanotan II is the structural ancestor of PT-141: researchers derived bremelanotide from it by replacing the C-terminal amide with a carboxylic acid, which reduced unwanted receptor activity. Melanotan II itself never completed late-phase clinical trials for any indication. It is not approved by the FDA, EMA, or any other regulator. Meaningful safety cautions are documented in case reports, including new and changing moles, priapism, renal injury and rhabdomyolysis. Any new or changing mole during or after use requires prompt dermatological assessment. This page summarizes what was studied; it lists no human dose.

What it is

Melanotan II is a truncated, cyclized, D-Phe-substituted derivative of the core alpha-MSH sequence (residues 4-10). Molecular formula C50H69N15O9. The cyclic lactam structure gives it enzymatic resistance and superpotent melanotropic activity relative to linear alpha-MSH. It is distinct from two separately approved compounds that are sometimes confused with it: afamelanotide (Melanotan I, the linear analog, approved for the rare condition erythropoietic protoporphyria) and bremelanotide/PT-141 (the derivative approved for HSDD in premenopausal women). Those approvals and their controlled-trial safety data do not extend to Melanotan II ^[16]. Melanotan II is handled strictly as a research chemical.

How it works

The mechanism branches by receptor. At MC1R on melanocytes, Melanotan II raises intracellular cAMP, driving the PKA-CREB-MITF cascade that upregulates tyrosinase and shifts pigment synthesis toward eumelanin — producing skin and hair darkening without requiring UV exposure. Central MC4R and MC3R activation in the hypothalamus and mesolimbic system mediates the appetite-suppressing, pro-erectile and sexual-motivation effects ^[16].

The appetite effects are partly mesolimbic: in male mice, Melanotan II microinjected bilaterally into the nucleus accumbens significantly decreased food consumption and appetitive responding for food, without producing conditioned taste aversion or altering metabolic rate — a selective mesolimbic effect ^[14].

The erectile effect documented in early human work is understood as central MC4R agonism in the same hypothalamic circuits studied for PT-141, consistent with the shared sequence core ^[17]. The key difference from PT-141 is the receptor promiscuity: MC1R activation drives the pigmentation and is also associated with the mole and melanocyte safety concerns.

What the research shows

Early human erectogenic study (n=10, double-blind, placebo-controlled crossover). Subcutaneous Melanotan II (0.025 mg/kg) produced clinically apparent erections in 8 of 10 men with psychogenic erectile dysfunction; mean duration of >80% tip rigidity was 38.0 minutes with MT-II versus 3.0 minutes with placebo (p=0.0045). Transient nausea, stretching and yawning required no treatment ^[17].

Melanocortin peptide lineage (review, 2006). A historical review documents that Melanotan I was clinically tested for skin tanning, Melanotan II for male erectile dysfunction, and that the PT-141 derivative advanced toward pivotal trials and commercialization for sexual dysfunction. This establishes the MT-I / MT-II / PT-141 lineage and the receptor basis of their divergent profiles ^[16].

Mesolimbic appetite (mice, 2022). Nucleus accumbens microinjection of Melanotan II selectively reduced food consumption and appetitive responding without aversion or metabolic-rate change — characterizing the mesolimbic melanocortin signaling pathway ^[14].

Oral-mucosal pigmentation (case report, 2026). Self-administration of 400 ug subcutaneously every other day for 64 days produced brown pigmentation on the attached gingiva and buccal mucosa, with buccal fading beginning at 28 days post-cessation while gingival pigmentation persisted at 3 months ^[13].

Renal infarction (case report and literature review, 2020). Renal infarction was attributed to Melanotan II; the authors identified previous rhabdomyolysis and renal failure reports and proposed thrombotic pharmacological influence and direct renal parenchymal toxicity as possible mechanisms ^[15].

Reported effects, cautions & safety

Melanotan II carries the most serious safety profile of the three compounds on this desk. Several cautions are documented in case reports and dermatology literature.

Cited safety cautions from the literature:

• New, changing or darkening moles — melanoma risk. As a non-selective MC1R agonist, Melanotan II drives melanocyte activity throughout the skin. Case reports document eruptive new nevi, dysplastic nevi, and melanoma arising in users. Dermoscopy studies show measurable melanocytic-lesion changes during use. Any new or changing mole during or after use warrants prompt dermatological assessment.
• Renal infarction and rhabdomyolysis. Published case reports describe renal infarction and rhabdomyolysis with acute kidney injury in association with MT-II use, with proposed thrombotic and direct-toxic mechanisms ^[15].
• Priapism. Prolonged, painful erection requiring emergency treatment has been documented in case reports — a consequence of the same central melanocortin erectogenic mechanism.
• Posterior reversible encephalopathy syndrome (PRES). A case report describes PRES (brain swelling presenting with headache, seizures, visual disturbance and hypertension) in association with melanotan use.
• Nausea and blood-pressure effects. Nausea is very common, typically peaking in the first hour after a dose and easing over time but persisting in many users. Preclinical hemodynamic work indicates melanocortin agonists can raise blood pressure ^[16].
• Unregulated supply. Analytical studies of melanotan products bought online repeatedly find inaccurate labeling, variable peptide content and impurities. The actual identity, dose, purity and sterility of a purchased vial are unknown.
• No regulatory approval; unknown long-term safety. Not approved by the FDA, EMA, TGA, MHRA or any other major regulator. Multiple regulatory bodies have issued specific warnings against melanotan tanning products.

Field reports (anecdotal, not clinical evidence):

People in research-use communities frequently describe a rapid, strong tan with less UV exposure than usual. Men commonly report a surge in libido and spontaneous erections, sometimes within hours of the first dose — welcome to some, uncomfortable or disruptive to others. Nausea is consistently described as worst when starting out and settling over time. Darkening of existing moles, appearance of new spots, facial flushing and a distinctive urge to stretch and yawn are very frequently mentioned. Fatigue in the first days is a recurring report. Some describe the color fading unevenly over weeks to months after stopping, with moles sometimes remaining permanently darker. These are anecdotal observations, reported separately from the cited clinical data, and carry no dosing implication.

Where it fits in desire and arousal research

Melanotan II sits at the structural origin of the melanocortin sexual-function story: it is the compound from which PT-141 was derived and from which the modern understanding of central melanocortin desire signaling grew ^[16]. Where PT-141 represents what targeted refinement can achieve — one approved indication with a characterized safety profile — and Kisspeptin acts on a completely separate axis, Melanotan II illustrates the cost of receptor promiscuity. The same broad melanocortin activity that made it interesting also makes it the compound with the most serious cautions on this desk. See the comparison page for the side-by-side.